Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10389MR)

This product GTTS-WQ10389MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10389MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2077MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ1005MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ8508MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ1376MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ10584MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ11038MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ12706MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ920MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW